NCT03918499 - IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 19, 2019

Primary Completion Date

February 9, 2023

Study Completion Date

February 9, 2023

Conditions

Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVB Gastric Cancer AJCC v8Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaPathologic Stage IV Gastric Cancer AJCC v8Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Recurrent Gastric AdenocarcinomaRecurrent Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Cytokine-based Biologic Agent IRX-2

Given SC

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (3)

75246

Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas

85258

HonorHealth Research Institute, Scottsdale

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER